<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our previous studies showed that <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi> <z:chebi fb="0" ids="25029">leukotriene</z:chebi> receptor-1 (CysLT1) <z:chebi fb="68" ids="48706">antagonist</z:chebi> pranlukast has a neuroprotective effect on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats and mice </plain></SENT>
<SENT sid="1" pm="."><plain>However, whether the neuroprotective effect of pranlukast is its special action or a common action of CysLT1 receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> remains to be clarified </plain></SENT>
<SENT sid="2" pm="."><plain>This study was performed to determine whether <z:chebi fb="0" ids="50730">montelukast</z:chebi>, another CysLT1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, has the neuroprotective effect on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice, and to observe its dose- and time-dependent properties </plain></SENT>
<SENT sid="3" pm="."><plain>Permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50730">Montelukast</z:chebi> was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and <z:chebi fb="0" ids="31530">edaravone</z:chebi> were used as controls </plain></SENT>
<SENT sid="5" pm="."><plain>The neurological deficits, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes, <z:hpo ids='HP_0002181'>brain edema</z:hpo>, neuron density, and Evans blue extravasation in the brain were determined 24 h after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Pretreatments with multiple doses or a single dose of <z:chebi fb="0" ids="50730">montelukast</z:chebi> (0.1 and 1.0 mg/kg) before MCAO significantly attenuated <z:hpo ids='HP_0000001'>all</z:hpo> the ischemic insults </plain></SENT>
<SENT sid="7" pm="."><plain>Post-treatment with a single dose of <z:chebi fb="0" ids="50730">montelukast</z:chebi> (0.1 and 1.0 mg/kg) at 30 min after MCAO also significantly decreased <z:hpo ids='HP_0002181'>brain edema</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, but not neurological deficits </plain></SENT>
<SENT sid="8" pm="."><plain>However, post-treatment with a single dose of <z:chebi fb="0" ids="50730">montelukast</z:chebi> at 1 h after MCAO had no significant effect </plain></SENT>
<SENT sid="9" pm="."><plain>Pranlukast showed the same effects as <z:chebi fb="0" ids="50730">montelukast</z:chebi>, but <z:chebi fb="0" ids="31530">edaravone</z:chebi> attenuated the ischemic insults only with multiple doses before MCAO </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, <z:chebi fb="0" ids="50730">montelukast</z:chebi> has a dose- and time-dependent neuroprotective effect on permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice, with an effective dose range of 0.1-1.0 mg/kg and a therapeutic window of 30 min </plain></SENT>
<SENT sid="11" pm="."><plain>These findings further support the therapeutic potential of CysLT1 receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> in the treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> at earlier phases </plain></SENT>
</text></document>